ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 785

Incidence, Prevalence and Survival of Biopsy-Proven Giant Cell Arteritis in Northern Italy

Mariagrazia Catanoso1, Pierluigi Macchioni1, Luigi Boiardi1, Francesco Muratore1, Giovanna Restuccia2, Alberto Cavazza3, Ferdinando Luberto4 and Carlo Salvarani1, 1Rheumatology Unit, Arcispedale S Maria Nuova, Reggio Emilia, Italy, 2Rheumatology Unit, Arcispedale S Maria Nuova, Reggio Emilia, Italy, 3Pathology Unit, Arcispedale S Maria Nuova, Reggio Emilia, Italy, 4Statistical Service, Azienda Usl Reggio Emilia, Reggio Emilia, Italy

Meeting: 2014 ACR/ARHP Annual Meeting

Keywords: biopsies, epidemiologic methods and giant cell arteritis

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Title: Vasculitis

Session Type: Abstract Submissions (ACR)

Background/Purpose: To investigate the incidence, prevalence and mortality of biopsy proven giant cell arteritis (GCA) over a 27-year period in a defined area of northern Italy.

Methods: All patients with incident GCA diagnosed from January 1, 1986 to December 31, 2012 living in the Reggio Emilia area were identified through computerized hospital discharge diagnosis and a structured review of all histopahology reports. Patients were followed up from the time of diagnosis until either their death or December 31, 2012.

Results: Two hundred and eighty-five patients (75 men and 210 women) had biopsy proven GCA according to the histopathological examination. Mean+SD age at diagnosis was 74.4+7.3 years. The mean annual incidence rate (IR) of GCA was 58.16/106 (95% CI: 51.4-64.9). The mean IR was 31.1/106 (95% CI: 26.9-35.4) among women and 11.6/106 (95% CI: 8.9-14.2) for men (p < 0.05). The estimated incidence for people over 50 y was 78.11 (95% CI: 67.4-88.7) for women and 33.4 (95% CI: 25.7-41) for men. The lowest IR occurred in male patients in the 50-59 years age group (5.13/106; 95% CI: 1.4-13.1), the highest IR was observed in female patients 80-84 years age group (215.4/106; 95% CI: 184.7-297.2). IR difference between sex was significant only in the 60-69 age group  (IR male/female 14.6/67.1, 95% CI 7.0-26.9 vs 49.8-88.4).  The average annual IR increased from 5.63/106 during 1986-1988  to 45.23/106 during 1998-2000 period and was stable thereafter with IR of   30-23/106. Point prevalence on December 31st 2012 was 304.5/106 (95% CI: 258.0-355.7) (women 453.1, 95% CI: 376-541.4, men 148.8, 95% CI: 105.3-204.2).

At histological examination 13.6% (39 pts) had only small vessels perivascular involvement (adventitial vasa vasorum and peri-adventitial capillaries). Prevalence of small vessels involvement was significant higher among male patients (male 30% vs 7%female, p< 0.001). One hundred and twenty-nine patients (45.2%) died during the follow-up period (median survival after diagnosis 152 months [range 4-320 months]). Survival did not differ nor between gender or between different histopathological pattern

Conclusion: This population-based study is the first to report the incidence of biopsy proven GCA in Italy. Our average annual IR is similar to that reported in the period 1984-1988 in Finland (1).

References 1)Franzén P, Sutinen S, von Knorring J. Giant cell arteritis and polymyalgia rheumatica in a region of Finland: an epidemiologic, clinical and pathologic study, 1984-1988. J Rheumatol. 1992; 19:273-6.


Disclosure:

M. Catanoso,
None;

P. Macchioni,
None;

L. Boiardi,
None;

F. Muratore,
None;

G. Restuccia,
None;

A. Cavazza,
None;

F. Luberto,
None;

C. Salvarani,
None.

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2014 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/incidence-prevalence-and-survival-of-biopsy-proven-giant-cell-arteritis-in-northern-italy/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology